aspirin has been researched along with Hepatitis B, Chronic in 13 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Hepatitis B, Chronic: INFLAMMATION of the LIVER in humans caused by HEPATITIS B VIRUS lasting six months or more. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Several studies have demonstrated chemopreventive effects of aspirin against hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB)." | 8.31 | Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B. ( Cho, EJ; Chung, JW; Kim, YJ; Lee, CH; Lee, J; Lee, JH; Lee, YB; Moon, H; Yoon, JH; Yu, SJ, 2023) |
| "Despite the overall association of aspirin on reduced hepatocellular carcinoma (HCC) risk, there have been few studies on its benefit according to specific clinical conditions among hepatitis B virus (HBV)-infected patients." | 8.12 | Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study. ( Ahn, SH; Kim, BK; Yoon, JH; Yun, B, 2022) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | 8.02 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "Aspirin and statins have been suggested to prevent hepatocellular carcinoma (HCC)." | 8.02 | Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. ( Choi, SH; Choi, WM; Han, S; Jo, AJ; Kim, HJ; Ko, MJ; Lim, YS, 2021) |
| "More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection." | 7.96 | Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. ( Aleman, S; Chan, AT; Chung, RT; Duberg, AS; Ludvigsson, JF; Simon, TG, 2020) |
| "Aspirin use was associated with reduced risks of HCC and liver-associated mortality in adults with CHB." | 5.72 | Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. ( Cho, EJ; Chung, JW; Jang, H; Kim, YJ; Lee, J; Lee, JH; Lee, YB; Moon, H; Nam, JY; Yoon, JH; Yu, SJ, 2022) |
| "Antiviral therapy cannot erase hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B, and it is not indicated for most hepatitis B virus (HBV) carriers." | 5.51 | Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. ( Hsu, YC; Lee, TY; Lin, JT; Tseng, HC; Wu, CY; Wu, MS; Yu, SH, 2019) |
| "Several studies have demonstrated chemopreventive effects of aspirin against hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB)." | 4.31 | Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B. ( Cho, EJ; Chung, JW; Kim, YJ; Lee, CH; Lee, J; Lee, JH; Lee, YB; Moon, H; Yoon, JH; Yu, SJ, 2023) |
| "Despite the overall association of aspirin on reduced hepatocellular carcinoma (HCC) risk, there have been few studies on its benefit according to specific clinical conditions among hepatitis B virus (HBV)-infected patients." | 4.12 | Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study. ( Ahn, SH; Kim, BK; Yoon, JH; Yun, B, 2022) |
| "Aspirin may reduce the risk of chronic hepatitis B (CHB)-related hepatocellular carcinoma (HCC) in patients receiving antiviral treatment." | 4.02 | Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog. ( Chan, HL; Hui, VW; Lui, GC; Tse, YK; Wong, GL; Wong, VW; Yip, TC, 2021) |
| "Aspirin and statins have been suggested to prevent hepatocellular carcinoma (HCC)." | 4.02 | Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study. ( Choi, SH; Choi, WM; Han, S; Jo, AJ; Kim, HJ; Ko, MJ; Lim, YS, 2021) |
| "More information is needed about the long-term effects of low-dose aspirin (≤160 mg) on incident hepatocellular carcinoma, liver-related mortality, and gastrointestinal bleeding in persons with chronic hepatitis B or hepatitis C virus infection." | 3.96 | Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality. ( Aleman, S; Chan, AT; Chung, RT; Duberg, AS; Ludvigsson, JF; Simon, TG, 2020) |
| " Built on these observations, a recent preclinical study took advantage of a previously established hepatitis B virus (HBV) transgenic mouse model of immune-mediated chronic hepatitis that progresses to hepatocellular carcinoma (HCC), to demonstrate that clinically achievable doses of the anti-platelet drugs aspirin and clopidogrel - administered continuously after the onset of liver disease - can prevent hepatocarcinogenesis and greatly improve overall survival." | 3.79 | Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma. ( Guidotti, LG; Iannacone, M; Sitia, G, 2013) |
| "Aspirin use was associated with reduced risks of HCC and liver-associated mortality in adults with CHB." | 1.72 | Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis. ( Cho, EJ; Chung, JW; Jang, H; Kim, YJ; Lee, J; Lee, JH; Lee, YB; Moon, H; Nam, JY; Yoon, JH; Yu, SJ, 2022) |
| "Antiviral therapy cannot erase hepatocellular carcinoma (HCC) risk in patients with chronic hepatitis B, and it is not indicated for most hepatitis B virus (HBV) carriers." | 1.51 | Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. ( Hsu, YC; Lee, TY; Lin, JT; Tseng, HC; Wu, CY; Wu, MS; Yu, SH, 2019) |
| "Recurrence of hepatocellular carcinoma (HCC) with unsatisfactory survival is common after surgical resection." | 1.43 | Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection. ( Chao, Y; Chen, CC; Chen, TJ; Hu, YW; Huang, YH; Huo, TI; Lee, PC; Lin, HC; Liu, CJ; Su, CW; Wu, JC; Yeh, CM, 2016) |
| "Treatment with aspirin and clopidogrel during the chronic phase of the disease diminished the number of intrahepatic HBV-specific CD8(+) T cells and HBV-nonspecific inflammatory cells, the severity of liver fibrosis, and the development of HCC." | 1.38 | Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. ( Aiolfi, R; Chisari, FV; Di Lucia, P; Esposito, A; Fiocchi, A; Guidotti, LG; Iannacone, M; Mainetti, M; Mingozzi, F; Ruggeri, ZM; Sitia, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 8 (61.54) | 2.80 |
| Authors | Studies |
|---|---|
| Jang, H | 1 |
| Lee, YB | 2 |
| Moon, H | 2 |
| Chung, JW | 2 |
| Nam, JY | 1 |
| Cho, EJ | 2 |
| Lee, JH | 2 |
| Yu, SJ | 2 |
| Kim, YJ | 2 |
| Lee, J | 2 |
| Yoon, JH | 3 |
| Yun, B | 1 |
| Ahn, SH | 1 |
| Kim, BK | 1 |
| Lee, CH | 1 |
| Zhao, J | 1 |
| Huang, R | 1 |
| Zhang, Z | 1 |
| Wang, J | 1 |
| Zhang, S | 1 |
| Wu, C | 1 |
| Simon, TG | 1 |
| Duberg, AS | 1 |
| Aleman, S | 1 |
| Chung, RT | 1 |
| Chan, AT | 1 |
| Ludvigsson, JF | 1 |
| Hui, VW | 1 |
| Yip, TC | 1 |
| Wong, VW | 1 |
| Tse, YK | 1 |
| Chan, HL | 1 |
| Lui, GC | 1 |
| Wong, GL | 1 |
| Choi, WM | 1 |
| Kim, HJ | 1 |
| Jo, AJ | 1 |
| Choi, SH | 1 |
| Han, S | 1 |
| Ko, MJ | 1 |
| Lim, YS | 1 |
| Lee, TY | 1 |
| Hsu, YC | 1 |
| Tseng, HC | 1 |
| Yu, SH | 1 |
| Lin, JT | 1 |
| Wu, MS | 1 |
| Wu, CY | 1 |
| Fox, RK | 1 |
| Taddei, TH | 1 |
| Kaplan, DE | 1 |
| Sitia, G | 2 |
| Iannacone, M | 2 |
| Guidotti, LG | 2 |
| Lee, PC | 1 |
| Yeh, CM | 1 |
| Hu, YW | 1 |
| Chen, CC | 1 |
| Liu, CJ | 1 |
| Su, CW | 1 |
| Huo, TI | 1 |
| Huang, YH | 1 |
| Chao, Y | 1 |
| Chen, TJ | 1 |
| Lin, HC | 1 |
| Wu, JC | 1 |
| Aiolfi, R | 1 |
| Di Lucia, P | 1 |
| Mainetti, M | 1 |
| Fiocchi, A | 1 |
| Mingozzi, F | 1 |
| Esposito, A | 1 |
| Ruggeri, ZM | 1 |
| Chisari, FV | 1 |
13 other studies available for aspirin and Hepatitis B, Chronic
| Article | Year |
|---|---|
Aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B with or without cirrhosis.
Topics: Adult; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Incidence | 2022 |
Clinical Indication of Aspirin Associated With Reduced Risk of Liver Cancer in Chronic Hepatitis B: A Nationwide Cohort Study.
Topics: Aspirin; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis B virus; Hepatitis B, Chronic; | 2022 |
Association between daily aspirin therapy and risk of hepatocellular carcinoma according to metabolic risk factor burden in non-cirrhotic patients with chronic hepatitis B.
Topics: Adult; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Hepatitis B, Chronic; Humans; Liver Neo | 2023 |
Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li | 2023 |
Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; Humans; Li | 2023 |
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Female; Gastroin | 2020 |
Aspirin Reduces the Incidence of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Receiving Oral Nucleos(t)ide Analog.
Topics: Adult; Aged; Alanine; Antiviral Agents; Aspirin; Carcinoma, Hepatocellular; Drug Therapy, Combinatio | 2021 |
Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population-based study.
Topics: Aspirin; Carcinoma, Hepatocellular; Case-Control Studies; Hepatitis B, Chronic; Humans; Hydroxymethy | 2021 |
Association of Daily Aspirin Therapy With Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Carcinoma, Hepatocellular; Cohort Studies; | 2019 |
Aspirin Use and Risk of Hepatocellular Carcinoma in Hepatitis B.
Topics: Aspirin; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis B, Chronic; Humans; Liver Neoplasms | 2019 |
Anti-platelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma.
Topics: Animals; Aspirin; Blood Platelets; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Proli | 2013 |
Antiplatelet Therapy is Associated with a Better Prognosis for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma after Liver Resection.
Topics: Adult; Aged; Aspirin; Carcinoma, Hepatocellular; Clopidogrel; Disease-Free Survival; Female; Gastroi | 2016 |
Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B.
Topics: Analysis of Variance; Animals; Aspirin; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Clopi | 2012 |